# Programme

## Thursday, 22 April 2027

### GDAŃSK, POLAND | 22–24 APRIL 2027

| | |
|---|---|
| 19:00 | **Get-together (Faculty Only)** |

## Friday, 23 April 2027

### GDAŃSK, POLAND | 22–24 APRIL 2027

| | |
|---|---|
| 08:30–08:35 | **Welcome**<br>*prof. dr hab. n. med. Krzysztof Narkiewicz, prof. Michel Burnier* |
| 08:35–09:50 | **Session 1. From biomarkers to clinical decisions — what really changes practice?**<br><br>*Chairs: prof. dr hab. n. med. Andrzej Januszewicz, prof. Alexandre Persu* |
| 08:35–08:50 | Why do we need biomarkers — what do they add beyond conventional risk factors?<br>*Carmine Zoccali* |
| 08:50–09:05 | Different biomarkers, different questions<br>*Francesca Mallamaci* |
| 09:05–09:20 | From association to clinical utility — how should a new biomarker be validated?<br>*prof. Christian Delles* |

| | |
|---|---|
| 09:20–09:35 | When should a biomarker change treatment? |
| 09:35–09:50 | Discussion |
| 09:50–10:10 | **Coffee break** |
| 10:10–12:10 | **Session 2. Hypertension in 2027: promises and disappointments in biomarkers, risk stratification and treatment targets** |
| 10:10–10:25 | Homocysteine and B vitamins — old story, new evidence? |
| 10:25–10:40 | Inflammation and vascular dysfunction in hypertension — does hsCRP add value?<br>*Daniela Carnevale* |
| 10:40–10:55 | hs-Troponin and NT-proBNP — ready for risk stratification in hypertension?<br>*prof. Gianfranco Parati* |
| 10:55–11:10 | MicroRNAs — still promising or a missed opportunity? |
| 11:10–11:25 | Renin and aldosterone — can we use them to guide treatment? |
| 11:25–11:40 | Sympathetic activation — can we identify and treat the phenotype?<br>*Stefano Masi* |
| 11:40–12:10 | Discussion |
| 12:30–14:00 | **Lunch** |
| 14:00–16:00 | **Session 3. Biomarkers in CKD — from progression to nephroprotective treatment**<br>*Chairs: Liffert Vogt, prof. Michel Burnier* |
| 14:00–14:15 | New blood and urine biomarkers — do they improve risk prediction? |

| | |
|---|---|
| 14:15–14:30 | Tubular biomarkers — can they improve assessment of kidney injury and progression?<br>*. Marius Miglinas* |
| 14:30–14:45 | Albuminuria and eGFR slope — still the benchmarks?<br>*Alberto Ortiz* |
| 14:45–15:00 | Afamin — promising biomarker or another association? |
| 15:00–15:15 | pre-CKD (hrCKD) — new clinical entity in nephrology defined by biomarkers<br>*prof. dr hab. n. med. Marcin Adamczak* |
| 15:15–15:30 | From risk prediction to treatment selection — can biomarkers guide nephroprotection?<br>*prof. dr hab. n. med. Andrzej Więcek* |
| 15:30–16:00 | Discussion |
| 16:00–16:20 | **Coffee break** |
| 16:25–17:35 | **Session 4. Heart Failure: from biomarkers to precision therapy and proactive care**<br>*Chairs: prof. Gianfranco Parati, Piotr Ponikowski* |
| 16:25–16:32 | From molecular signatures to treatable endotypes: can multi-omics guide heart failure therapy? |
| 16:32–16:44 | Precision decongestion: urine sodium and beyond<br>*dr hab. n. med., prof. UMW Jan Biegus* |
| 16:44–16:56 | From blood tests to biosensors: towards real-time monitoring in heart failure |
| 16:56–17:08 | From multi-modal monitoring to supported self-management: can we prevent worsening heart failure? |
| 17:08–17:20 | Biomarker-guided precision medicine in heart failure: promise or clinical reality?<br>*prof. dr hab. n. med. Ewa Jankowska* |

| | |
|---|---|
| 17:20–17:35 | Panel discussion: from biomarker signals to clinical decisions — what is ready for practice? |

# Saturday, 24 April 2027

## GDAŃSK, POLAND | 22–24 APRIL 2027

| | |
|---|---|
| 09:00–10:15 | **Session 5. Beyond blood biomarkers — digital phenotyping and imaging** |
| 09:00–09:15 | Digital biomarkers in peripheral artery disease — ready for clinical use? |
| 09:15–09:30 | Renal MRI biomarkers — from tissue characterization to clinical decisions |
| 09:30–09:45 | Imaging biomarkers for Kidney Function and Disease: MRI and beyond<br>*dr Anna Caroli* |
| 09:45–10:00 | Cardiac CT and MRI biomarkers — what changes clinical management? |
| 10:00–10:15 | Discussion |
| 10:15–10:35 | **Coffee break** |
| 10:35–11:50 | **Session 6. The future of biomarkers — what comes next?**<br>*Chairs: dr Jan Danser, prof. dr hab. n. med. Krzysztof Narkiewicz* |
| 10:35–10:50 | From biomarkers to physiology — what can we learn from the kidney? |
| 10:50–11:05 | Will genetic biomarkers change clinical practice?<br>*Olle Melander* |

| | |
|---|---|
| 11:05–11:20 | Risk assessment in hypertension — where will biomarkers fit? |
| 11:20–11:35 | From cardiovascular risk prediction to treatment — which biomarkers will really matter in 2030? |
| 11:35–11:50 | Discussion |
| 11:50–12:30 | **Discussion and closure of the meeting**<br>*Chairs: prof. dr hab. n. med. Krzysztof Narkiewicz, prof. Michel Burnier* |
| 13:00 | **Lunch** |